09:55 AM EST - Resverlogix Corp. : Announced that the independent Data and Safety Monitoring Board for the Company's Phase 3 BETonMACE trial in high-risk cardiovascular patients has completed a planned safety review and verbally recommended that the study should continue as planned without any modifications. Resverlogix Corp.
shares T.RVX are trading up $0.03 at $1.19.
